



Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and COO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<https://www.daiichisankyo.com>

Daiichi Sankyo Announces Transfer of Daiichi Sankyo Propharma Takatsuki Plant and Company Split (Simple Absorption-type Company Split) (Update on previously disclosed item)

Tokyo, Japan (May 31, 2019) - Daiichi Sankyo Company, Limited (hereafter, the Company), today announced that its Board of Directors Meeting has resolved to conclude a company split agreement for the land and structures of Takatsuki plant owned by the Company, for the purpose of transferring them to TAIYO Pharma Tech Co., Ltd. prior to transferring Takatsuki plant (owned by the Company's subsidiary, Daiichi Sankyo Propharma Co., Ltd.) to Taiyo Holdings Co., Ltd.

As a side note, TAIYO Pharma Tech Co., Ltd. is a 100% subsidiary of the Company which has been newly established for the purpose of transferring Takatsuki plant to Taiyo Holdings Co., Ltd.

This announcement is an update on the previous announcement, "Daiichi Sankyo Announces Transfer of Daiichi Sankyo Propharma Takatsuki Plant and Company Split (Simple Absorption-type Company Split)," disclosed on January 31, 2019. Please refer to the previously disclosed document for further details.

1. Summary of Daiichi Sankyo's Company Split

1) Timeline for the Company Split

Board of Directors resolution date (Daiichi Sankyo)	May 31, 2019
Contract conclusion date	May 31, 2019
Effective date	October 1, 2019 (schedule)

(Note) Since this Company Split is a simplified absorption-type split into a 100% subsidiary, based on provisions of Article 784, Paragraph 2 of the Companies Act, the split is being implemented without resolution at general shareholders' meeting.

2. Outline of the Party for the Company Split

【Successor Company】

1. Company name	TAIYO Pharma Tech Co., Ltd.
2. Address	4-38, Aketa-cho, Takatsuki-shi, Osaka, Japan
3. Representative's title and name	Junichi Fukute, Representative Director, President
4. Business contents	Contract manufacturing of pharmaceuticals, etc.
5. Share Capital	¥300 million
6. Establishment date	April 25, 2019
7. Number of shares issued	6,000 shares
8. Fiscal year-end	March 31
9. Major shareholder and shareholding ratio (as of May 31, 2019)	Daiichi Sankyo Company, Limited : 100%

3. Outline of the Company Split

1) Split Assets and Liabilities Items and Amounts (as of March 31, 2019)

Assets		Liabilities	
Item	Book Value	Item	Book Value
Current assets	—	Current liabilities	—
Fixed assets	¥65 million	Fixed liabilities	—
Total	¥65 million	Total	—

(Note1) The book value of the fixed assets decreased due to depreciation compared to the book value as of March 31, 2018, which was disclosed on January 31, 2019.

(Note2) The amounts of the split assets and liabilities will be determined considering increases and decreases to the above-stated amounts until the day before the date the Company Split comes into effect.